


# SEPARATION AND ENRICHMENT OF STABLE ISOTOPES



Isotec is the world's leading commercial producer of enriched stable isotopes, with a large inventory of labelled starting materials, intermediates, and final products to meet our customers' varied needs. We are capable of producing large volumes, and Long Term Blanket Agreements are available.

- Amino Acids & Derivatives
- Carbohydrates
- Intermediates
- Agricultural Compounds
- Call us with your Custom Synthesis requirements

Quality Products • Excellent Service  
Competitive Prices

**ISOTEC INC.**  
A Matheson, USA Company

Stable Isotopes For Research & Industry  
3858 Benner Road, Miamisburg, OH 45342  
(513) 859-1808 (800) 448-9760  
Telex: 288278 FAX: (513) 859-4878

more detailed appraisal does not support this stance. The conversion of R to S enantiomer in vivo is incomplete (1), being largely (60%) independent of the size and enantiomeric composition of the administered dose. The clearance of each enantiomer is also independent of the administered dose (2). These observations should be set in the context of findings from clinical trials that twice the dose of racemic ibuprofen is needed to attain the same plasma concentration of S form as compared with the pure S enantiomer (3). In plain language, the S enantiomer of ibuprofen is a better drug than the racemate.

Anti-inflammatory agents are typically administered over long time periods to rheumatoid arthritis patients and are not devoid of side effects. In such circumstances, it is surely imperative to minimize the dose. If the research findings cited are fully sustained, then a clear case will be made for the exclusive licensing of the S enantiomer of ibuprofen and the pursuit of enantiomerically pure drugs in general.

**John M. Brown**

Dyson Perrins Laboratory,  
Oxford University,  
South Parks Road,  
Oxford OX1 3QY,  
United Kingdom

## REFERENCES

1. A. C. Rudy, P. M. Knight, D. C. Baxter, S. D. Hall, *J. Pharmacol. Exp. Ther.* **259**, 1133 (1991).
2. A. M. Evans, R. L. Nation, L. N. Sansom, F. Bochner, A. A. Somogyi, *Biopharm. Drug Dispos.* **11**, 507 (1990).
3. G. Geisslinger et al., *Eur. J. Clin. Pharmacol.* **38**, 493 (1990).

## HIV-Free AIDS Reports

A 31 July News & Comment article by Jon Cohen about HIV (human immunodeficiency virus)-free AIDS cases reported at the VIII International AIDS Conference in Amsterdam (p. 604) ends with a call by Michael Merson "to launch 'a worldwide study of this situation' as quickly as possible." I am responding to this call with an offer to provide, to anyone who requests it, now [or later (1)] a list of references to more than 800 HIV-free immunodeficiencies and AIDS-defining diseases in all major American and European AIDS risk groups. In addition, I can provide references to more than 2200 HIV-free African AIDS cases that all meet the World Health Organization definition of AIDS (1). Each of these cases was diagnosed after the "AIDS test" for antibodies to HIV was introduced in 1984.

There may be more HIV-free AIDS-like cases, as only about 50% of all AIDS cases

reported by the Centers for Disease Control (CDC) are confirmed as HIV-positive (2, 3); the remainder are based on presumptive diagnoses (2, 4). Surprisingly, the CDC does not survey HIV in its monthly *HIV/AIDS Surveillance* reports (5).

Rather than rushing to a "new AIDS virus" as the explanation, *Science* could focus more attention on "[a]lternatives to a virus" that could resolve the growing paradoxes of the virus-AIDS hypothesis.

**Peter Duesberg**

Department of Molecular and Cell Biology,  
University of California,  
Berkeley, CA 94720

## REFERENCES

1. P. Duesberg, *Pharmacol. Ther.*, in press.
2. Institute of Medicine, *Confronting AIDS—Update 1988* (National Academy Press, Washington, DC, 1988).
3. R. M. Selik, J. W. Buehler, J. M. Karon, M. E. Chamberland, R. L. Berkelman, *J. Acq. Immune Defic. Syndr.* **3**, 73 (1990).
4. Centers for Disease Control, *J. Am. Med. Assoc.* **258**, 1143 (1987).
5. *HIV/AIDS Surveillance, 1991*, Centers for Disease Control, Atlanta, GA, 1992.

## Population Genetics: Founding Fathers

In his article "The evolution of sexes" (Research News, 17 July, p. 324), Alun Anderson describes Cambridge University's Ronald Fisher as "the founding father of modern population genetics." Fisher was indeed a great geneticist and a statistician. He was among the three founding fathers of modern population genetics (the other two were J. B. S. Haldane and S. Wright), but not the founding father!

**D. R. Govindaraju**

Department of Biology,  
Case Western University,  
10900 Euclid Avenue,  
Cleveland, OH 44106-7080

## Corrections and Clarifications

In the author note for the Nobel lecture "Soft matter" by P. G. de Gennes (24 Apr., p. 495), the last sentence should have read, "It is published here with the permission of the Nobel Foundation and will also be included in the complete volume *Les Prix Nobel 1991* (in English) as well as in *Nobel Lectures* (in English) to be published by Elsevier Publishing Company, Amsterdam and New York."

In figures 1B and 2C of the report "Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4<sup>+</sup> T cells" by P. U. Cameron et al. (17 July, p. 383), the y axes should have read, "RTase 10<sup>3</sup> CPM/ $\mu$ l." The last line of reference 20 should have read "agarose gel stained with ethidium bromide."